Skopje, Republic of Macedonia, 20-22 March 2015 (local hosts: Prof. Spasovski and Ms. Markoska). In brief, the iMODE-CKD program aims at integration of various "omics" datasets using systems biology and bioinformatics approaches in order to identify putative biomarkers of chronic kidney disease diagnosis and progression. BCMolMed similarly applies systems biology approaches with the main objecttive to increase understanding of bladder cancer invasiveness. Both programs share the same training objectives, i.e. training young investigators in systems biology approaches as applied to biomarker and therapeutic target discovery while increasing their multidisciplinary communication skills and working experience in academic and industrial settings.
A total of 40 researchers attended the meeting from over 13 countries (Fig. 1) . The purpose of the Workshop was to present current clinical management issues related to chronic kidney disease. A total of 15 oral presentations were given by renowned nephrologists and experts in multiple issues related to CKD. In addition, two presentations on complimentary skills (ethics in science and career advancement) were given by iMODE-CKD principle investigators.
Figure 1 -iMode-CKD and BCMolMed consortium members
The meeting was opened by Goce Spasovski (R. Macedonia) from the hosting institution. In his brief introduction he presented the Research Centre for Genetic Engineering and Biotechnology (RCGEB) and introduced local hosts from the organizing committee, Momir Polenakovic, Katerina Davalieva and Katerina Markoska.
A presentation by Katerina Davalieva (R. Macedonia) was then given, on proteomics research in prostate cancer (PCa), as applied in ongoing projects in RCGEB. Main scope of their research is the identification of biomarkers for PCa detection from urine samples by 2-dimensional electrophoresis, generating a large number of biomarkers candidates for PCa, complementing existing lists from the literature. Nevertheless, inconsistencies in sample collection, storage and processing methods as well as high inter-and intra-variability of body fluid samples impede data comparability and selection of biomarkers to be applied in clinical trials.
The Saturday training session started with Raymond Vanholder's (Belgium) presentation focusing on methods to decrease uremic toxins in dialysis patients. To remove middle molecules (β2-microglobulin) and protein-bound compounds (indoles, phenols), numerous solutions such as improvements in dialysis conditions, therapeutic treatments, and stem cells implanttation are currently explored. Progress in extracorporeal toxin removal can be achieved by increase in dialysis time (with higher dialysate flow and membrane surface area), use of novel matrix membranes (e.g. dual layer hollow fibers) or artificial kidney. Additional approaches include targeting uremic toxins throughout the intestine, by diet supported with therapeutics (prebiotics, probiotics, symbiotic, sorbents) and modification of metabolism.
Alberto Ortiz (Spain) covered issues related to the ever increasing prevalence of CKD. With the hypothesis that the "physiological" decrease in renal function is in fact an undiagnosed CKD condition, he proposed that novel biomarkers should focus on earlier detection of renal function loss. He also underlined the problem of CKD unawareness due to limited patient screening and lack of satisfactory diabetic kidney disease treatments, which is known to be the major contributor to ESRD (End Stage Renal Disease) occurrence.
Olivera Stojceva-Taneva (R. Macedonia) highlighted the need of accurate glomerular filtration rate (GFR) measurement and its importance in current diagnosis, prognosis and treatment of CKD patients. The level of GFR is used for clinical assessment of kidney function and disease severity, and it can be measured either by exogenous marker clearance (mGFR) or estimated based on blood creatinine level (eGFR). However, both forms of measurements have drawbacks, i.e. mGFR is measured with inulin which is an invasive marker and its clearance is altered by renal handling or extrarenal metabolism, whereas accuracy of eGFR is questioned due to high variability of serum creatinine levels, further underscoring the need for novel biomarkers.
Dimitrios Goumenos (Greece) explored the topic of proteinuria and its relation to chronic kidney disease progression emphasizing the need for novel biomarkers for identification of kidney scarring. Based on the observed renal fibrosis, the assumption that anti-cytokines or antifibrotic markers could reflect the early changes leading to interstitial fibrosis was supported.
Joachim Beige (Germany) deliberated over the complexity of CKD and its prevention (Fig.  2) . Methods of prevention vary depending on patients' condition and include basic diet adjustments, smoking avoidance, physical activity (primary prevention) or treatment of secondary phenomena that coexist with kidney diseases such as acidosis and hypertension (secondary prevention). Nevertheless, some questions regarding CKD progression remain unanswered, thus prevention methods should be tailored for individual patients, based on their clinical parameters.
Marian Klinger (Poland) characterized hypertension as an important factor in the mechanism of glomerulosclerosis, which in the majority of cases is connected with ischemic nephropathy among the elderly population. As proteinuria in not the only factor of CKD progresssion, he outlined the necessity of blood pressure monitoring and focusing on individual patient needs when making a clinical judgement and deciding on a diagnosis and further treatment.
Goce Spasovski presented on the topic of cardiovascular disease (CVD) in CKD, describing mineral and bone disorders. The abnormalities in calcium and phosphate homeostasis lead to hormonal (PTH secretion) and mineral (bone resorption) changes, which contribute to CVD development, increased morbidity and mortality. He investigated the use of bone biopsy for renal osteodystrophy diagnosis and methods of calcium administration in CVD treatment.
CKD-related cellular and molecular mechanisms as well as major disease complications were described in detail by Joachim Jankowski (Germany). Known cellular events that are present in CKD pathophysiological pathways include mesangial and fibroblast activetion, monocyte and macrophage differentiation, and T-cell activation. Decreased kidney function is often accompanied by complications such as anemia, CVD, mineral and bone disorders and dyslipidemia, and therefore, a broad understanding of CKD mechanisms is crucial in disease prevention and treatment.
Figure 2 -Complex pathogenesis of chronic kidney disease (CKD)
Adalbert Schiller (Romania) presented novel therapeutic targets aimed at inhibition of fibrotic and inflammatory factors, namely USF 1/2, TGF-β, CTGF that can be achieved by BMP-7 receptor stimulation, miR-192 downregulation, and inhibition of NF-κB pathway. Cytotoxic effects of oxidative stress can be managed by NADPH oxidase suppression or induction of Nuclear factor (erythroid-derived 2)-like 2 (Nrf2). He also reported ongoing research studies that are designed to slow down CKD progression. Furthermore, he described prospects and challenges of regenerative medicine in kidney disease treatment.
Robert Johnson (USA), a representative of the research-intensive biopharmaceutical company AbbVie, presented the modern drug discovery pipeline for 'next-generation' therapeutics development. This (pipeline) incorporates modern genomics, proteomics and metabolomics platforms that allow high-throughput molecular screening of biological samples and provide promising findings. Novel hypotheses are validated on large cohorts, followed by extensive clinical assessments and multi-year follow-ups before moving onto clinical trials. Future diagnostics and therapies will be crafted to meet each individual patients' needs.
Renal biopsy -the current "gold standard" for CKD diagnosis -was presented by Franco Ferrario (Italy). He underscored the importance of histological assessment due to the variability of lesions present in glomerular disease. Dr Ferrario has developed a training tool on CKD histopathology via posting images of kidney biopsies in the password-protected area of the iMODE-CKD website. Nowadays, kidney biopsy is still considered the ultimate test for accurate diagnosis, prognosis and selection of proper treatment.
The subsequent speech of Ivan Rychlik (Czech Republic) continued on the topic of renal biopsy with focus on the occurrence of non-diabetic renal disease (NDRD) among diabetic patients. The incidence of NDRD, that can have both glomerular and non-glomerular origin, is very high in type 2 diabetic patients, but only patients with atypical presentations undergo histological examination. For this reason, there is a need for a unified policy regarding patient classification.
Andrew Smith, who substituted his supervisor Fulvio Magni (Italy), spoke about mass spectrometry imaging (MSI), a technique that combines the detection of different classes of analytes and their spatial distribution that can be used for advanced tissue analysis. When combined with histological evaluation, matrixassisted laser desorption/ionization (MALDI) imaging, becomes a highly valuable tool in disease investigation.
Lectures aiming at acquiring competitive skills were also given: Joost Schanstra (France) presented an interesting approach of business SWOT analysis, as applied to personal skills assessment and career planning. Next, Goce Spasovski presented the complex subject of ethics in science that was followed by a very lively discussion among the audience. Ethical guidelines for medical research that are described in the Declaration of Helsinki and the Belmont report cover three fundamental principles: respect for persons, beneficence and justice. It is important to balance the aim of advancement in science with the protection of research subjects as a main priority.
The Regular Meeting included an open to the public session, dedicated to early stage researchers (ESRs). An introductory talk by Giovambattista Capasso (Italy) was given, descrybing the importance of aldosterone in CKD treatment. Aldosterone plays a significant role in the blood pressure regulatory system and hence in the pathogenesis of renal disease. The inhibitors of the renin-angiotensin-aldosterone system (RAAS) and angiotensin-converting enzymes (ACE) have shown renoprotective effects, as the reduction of blood pressure and proteinuria significantly decreases CKD progression, therefore the blockade of aldosterone pathway should be further investigated with regards to CKD therapy.
Subsequently, trainees within the iMODE-CKD and BCMolMed projects presented their achievements within the scope of their specific projects, describing current activities, future plans and accomplishments. Briefly, iMODE-CKD involves a total of 10 ESRs (i.e., Ph.D. students) and 1 ER (Experienced Researcher, i.e., postdoctoral trainee) covering a whole range of topics related to biomarker research in CKD, by application and integration of various "omics" techniques, such as proteomics, metabolomics, transcriptomics, supported by bioinformatics tools and systems biology approaches (Fig. 3) . BCMolMed, includes 3 Ph.D. students targeting validation of know bladder cancer biomarkers, comprehensive proteomics analysis of tissue and data integration by the use of systems biology approaches. In all cases significant progress towards achieving the program objectives has been made involving optimization of applied techniques, identification of promising biomarker candidates and development of first versions of CKD and bladder cancer specific databases as well as first disease models based on literature and "omics" data. The ESR session was followed by a discussion about the iMODE-CKD project progress as a whole and future plans related to both the scientific as well as training programs coordinated by Antonia Vlahou. 
